Is the Cause of Mitral Regurgitation Relevant for MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy: it is present in (at least) 7.5% of patients >75 years old.

This pathology can be classified as primary or degenerative MR (DMR) and secondary or functional MR (FMR).

 

FMR can be caused by dilatation of the left atrium (most often due to atrial fibrillation), occurring in 27% of cases (a-FMR), or by involvement of the ventricle, known as ventricular FMR (v-FMR).

Whether the MitraClip strategy is similar in these contexts is yet to be determined.

The analysis included a total of 1044 patients with MR. Among them, 423 had DMR and 621, FMR. Among the latter, 505 cases were v-FMR and 116, a-FMR.

The primary endpoint (PEP) was all-cause mortality and hospitalization due to heart failure at 2 years of follow-up.

The mean patient age was 76.3 years old; 40% of subjects were female and the Society of Thoracic Surgeons (STS) score was 8.6%.

Read also: Apixaban and Valve Thrombosis after TAVR.

Patients with v-FMR were younger, but had higher STS scores (9.3%). In the a-MRF group, there were more women and greater evidence of atrial fibrillation.

There were no differences in comorbidities nor in the New York Heart Association functional class.

In the echocardiographic findings, those with v-FMR had greater ejection fraction and larger ventricle diameters; those in the a-FMR group had a large left atrium and small ventricular diameters. In cases caused by DMF, the effective regurgitant orifice area was greater. No difference was observed as regards pressure in the pulmonary artery.

Read also: Mortality and Bleeding in Access Site Choice: Systematic Review.

There were no differences in procedure time, fluoroscopy time, or final outcome. Fewer clips were used in a-FMR patients.

The PEP was in favor of DMF compared with v-FMR and a-FMR (42.3% vs. 31.5% vs. 21.6%; p < 0.001), respectively.

Mortality was higher in those who presented a-FMR compared with DMR, and somewhat lower compared with those who presented v-FMR.

Read also: Can We Discharge TAVR Patients the Same Day?

The presence of tricuspid regurgitation was associated with higher mortality regardless of the cause of MR.

Conclusion

While procedural outcomes are excellent, patients with a-FMR and v-FMR have a worse clinical evolution than those with DMR.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling

Reference: Sung-Han Yoon, et al. J Am Coll Cardiol Intv 2022;15:1711–1722.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...